Novo Holdings trims MapLight (MPLT) ownership below 5% after share sales

Rhea-AI Filing Summary

Novo Holdings A/S filed an amendment reporting its ownership in MapLight Therapeutics, Inc. It beneficially owns 2,086,622 shares of voting common stock, representing 4.9% of MapLight’s outstanding common shares, based on 42,618,165 shares outstanding as of May 7, 2026.

On July 30, 2026, Novo Holdings sold MapLight shares in open market transactions, including 1,314,195 shares at $12.00 per share and additional blocks at weighted-average prices of $14.19 and $14.69. As of that date, the reporting persons ceased to be beneficial owners of more than five percent of MapLight’s common stock.

Key Figures

Beneficial ownership: 2,086,622 shares Percent of class: 4.9% Shares outstanding: 42,618,165 shares +4 more

7 metrics

Beneficial ownership 2,086,622 shares MapLight common shares beneficially owned by Novo Holdings A/S

Percent of class 4.9% Percentage of MapLight outstanding common stock represented by Novo Holdings A/S holdings

Shares outstanding 42,618,165 shares MapLight common shares outstanding as of May 7, 2026, from Form 10-Q

July 30 sale block 1 1,314,195 shares at $12.00 per share Open market sale by Novo Holdings on July 30, 2026

July 30 sale block 2 220,723 shares at $14.19 weighted-average price Open market sale in price range $13.55–$14.54 on July 30, 2026

July 30 sale block 3 65,082 shares at $14.69 weighted-average price Open market sale in price range $14.55–$15.00 on July 30, 2026

Ownership threshold date July 30, 2026 Date reporting persons ceased to be beneficial owners of more than five percent of MapLight’s common stock

Key Terms

beneficially owns, Sole Voting Power, Sole Dispositive Power, open market transactions

4 terms

beneficially owns financial

"Novo Holdings A/S beneficially owns 2,086,622 shares of common stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Sole Voting Power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Voting Power 2,086,622.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: Sole Dispositive Power 2,086,622.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

open market transactions financial

"sold the following shares in open market transactions"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 09:25 AM Accepted by SEC EDGAR 07/31/2026 - 09:25 AM Learn about SEC filing dates

FAQ

What ownership in MapLight Therapeutics (MPLT) does Novo Holdings report in this amendment?

Novo Holdings reports beneficial ownership of 2,086,622 MapLight voting common shares, representing approximately 4.9% of the company’s outstanding common stock, based on 42,618,165 shares outstanding as of May 7, 2026.

How many MapLight (MPLT) shares did Novo Holdings sell on July 30, 2026 and at what prices?

On July 30, 2026, Novo Holdings sold 1,314,195 shares at $12.00 per share, 220,723 shares at a weighted-average price of $14.19, and 65,082 shares at a weighted-average price of $14.69 in open market transactions.

When did Novo Holdings cease to be a more-than-5% owner of MapLight (MPLT)?

The reporting persons state they ceased to be beneficial owners of more than five percent of MapLight’s common stock on July 30, 2026, the date of the disclosed open market share sales.

What percentage of MapLight (MPLT) does Novo Holdings’ current stake represent?

Novo Holdings’ stake represents approximately 4.9% of MapLight’s outstanding common stock. This percentage is calculated using 42,618,165 shares outstanding as of May 7, 2026, as reported in MapLight’s Form 10-Q.

Does Novo Holdings have sole voting and dispositive power over its MapLight (MPLT) shares?

Novo Holdings reports sole voting power and sole dispositive power over 2,086,622 MapLight shares, with no shared voting or dispositive power. The filing states neither the Foundation nor listed individuals can direct voting or disposition of these shares.

Were there other recent MapLight (MPLT) share transactions by Novo Holdings or related parties?

The filing states that, except for the specified July 30, 2026 transactions, Novo Holdings, the Foundation, and persons listed on Schedule I have not effected any other transactions in MapLight common stock within the past 60 days.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

MAPLIGHT THERAPEUTICS, INC.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

56565P103

(CUSIP Number)

Barbara Fiorini
Novo Holdings A/S, Tuborg Havnevej 19,
Hellerup, G7, DK-2900
45 3527 6592

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/30/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 56565P103

1

Name of reporting person

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF, WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,086,622.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,086,622.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,086,622.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

4.9 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Voting Common Stock, par value $0.0001 per share
(b)	Name of Issuer: MAPLIGHT THERAPEUTICS, INC.
(c)	Address of Issuer's Principal Executive Offices: 800 Chesapeake Drive, Redwood City, CALIFORNIA , 94063.
Item 1 Comment: This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on November 4, 2025 (the "Statement") by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 5.	Interest in Securities of the Issuer
(a)	Novo Holdings A/S beneficially owns 2,086,622 shares of common stock representing approximately 4.9% of the Issuer's outstanding shares of common stock (the "Novo Shares"), based upon 42,618,165 shares of common stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.
(b)	Novo Holdings A/S is a Danish corporation wholly owned by the Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.
(c)	Except as set forth below, Novo Holdings A/S has not effected any transactions with respect to the Issuer's common stock during the past sixty days and neither the Foundation nor any person listed on Schedule I has effected any transactions in the Issuer's Common Stock within the past 60 days. On July 30, 2026, Novo Holdings A/S sold the following shares in open market transactions: - 1,314,195 shares of common stock in a single transaction at a price of $12.00 per share; - 220,723 shares of common stock at prices ranging from $13.55 to $14.54 per share (a weighted-average price of $14.19 per share); and - 65,082 shares of common stock at prices ranging from $14.55 to $15.00 per share (a weighted-average price of $14.69 per share).
(d)	Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.
(e)	The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on July 30, 2026.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Schedule I

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	/s/ Barbara Fiorini
Name/Title:	Novo Holdings A/S By Barbara Fiorini, General Counsel, Finance & Operations
Date:	07/31/2026